@article{Bhanwra_Mahajan_Kumar_2021, title={Lasmiditan: the first neurally acting anti-migraine drug}, volume={10}, url={https://www.ijbcp.com/index.php/ijbcp/article/view/4698}, DOI={10.18203/2319-2003.ijbcp20212088}, abstractNote={<p>Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5-HT<sub>1F</sub> agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.</p>}, number={6}, journal={International Journal of Basic & Clinical Pharmacology}, author={Bhanwra, Sangeeta and Mahajan, Sonia S. and Kumar, Rajiv}, year={2021}, month={May}, pages={745–747} }